Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.

Xuetian GaoLing PengLi ZhangKai HuangCuihua YiBei LiXue MengJisheng Li

Published in: Journal of cancer research and clinical oncology (2021)

Anlotinib is beneficial to refractory SCLC as third- or further-line treatment, especially in patients without liver metastasis and with better physical status. Related adverse effects are tolerable and manageable.

Keyphrases

small cell lung cancer
end stage renal disease
chronic kidney disease
newly diagnosed
physical activity
mental health
peritoneal dialysis
patient reported outcomes
replacement therapy